CClinicalTrials.gg
CompletedNCT05747963Updated Aug 6, 2024

Software-delivered CBT-I for Insomnia Disorder

An interventional study of software-delivered CBT-I and online PE in Insomnia Disorder, sponsored by Peking University Sixth Hospital. Completed at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Peking University Sixth Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this prospective multicenter clinical trial is to evaluate the efficacy and safety of software-delivered cognitive behavioral therapy for insomnia (CBT-I) in Chinese patients with insomnia disorder (ID). The main questions it aims to answer are: (1) whether the software-delivered CBT-I is more effective than an online patient education (online-PE) at improving insomnia. (2) whether the software-delivered CBT-I is safe for treatment of insomnia symptoms.

Participants will be randomized to receive (1) a software-delivered CBT-I using automated software called 'resleep' (one kind of digital device expected to treat insomnia targeted for Chinese patients); (2) online patient education (online-PE) about sleep.

Researchers will compare the efficacy of a software-delivered CBT-I program and an online sleep education control at improving insomnia symptoms and other psychological outcomes.

02

Conditions studied

  • Insomnia Disorder

Keywords

  • Insomnia Disorder
  • Software-delivered CBT-I
  • Randomised Clinical Trial
  • Digital Therapy
03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's enrollment of 236 is above the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Peking University Sixth Hospital is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged ≥18 years old, no gender limitation;
  • Own a mobile-phone, access the Internet, and be skilled in using software;
  • Meet the diagnostic criteria of insomnia disorder in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5);
  • Insomnia symptoms appear at least 3 nights per week and last for at least 3 months;
  • ISI scores ≥ 12 ;
  • Volunteer to participate in this experiment and sign a written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Generalized Anxiety Disorder Scale-7 (GAD-7) scores ≥ 15;
  • Patients Health Questionnaire-9 (PHQ-9) scores ≥ 20;
  • Current thoughts of suicide or self-injury (defined as PHQ-9 9th item score ≥ 1);
  • Confirmed physical diseases that may affect sleep, such as congestive heart failure, chronic obstructive pulmonary disease acute phase, cardiovascular and cerebrovascular disease acute phase, etc.
  • Current diagnosed neurological or mental illness (major depressive disorder, bipolar disorder, epilepsy, schizophrenia, etc.) that may affect sleep;
  • Diagnoses of other untreated sleep disorders, such as obstructive sleep apnea, restless leg syndrome (RLS);
  • Usual bedtime (when the subject attempts to fall asleep) is earlier than 8 p.m. or later than 2 a.m., or usual waking (arising) time is earlier than 4 a.m. or later than 10 a.m.
  • Alcohol or drug abusers (other than nicotine dependence) in the past year;
  • Pregnant or lactating women;
  • Undergoing systematic psychotherapy within the past 3 months;
  • Undergoing other cognitive behavioral therapy for sleep disorders;
  • Unstable usage of medication regimens that affect sleep (changes in type, dosage and method of use within the past 1 month);
  • Night shift workers, travelers across time zones;
  • Subjects who have not responded to previous CBT-I;
  • Other conditions deemed unsuitable for clinical trials by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    software-delivered CBT-I

    Subjects in intervention group will receive a digital CBT-I for 6 weeks. The automated software incorporates all core elements of CBT-I, tailoring content based on each participant's reported baseline sleep function and sleep progress.

    Device: software-delivered CBT-I

  • Active comparator
    online PE

    Subjects in control group will receive information about insomnia and sleep health education content.

    Other: online PE

Interventions

  • Devicesoftware-delivered CBT-I

    The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.

  • Otheronline PE

    Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.

06

What researchers measure

Primary outcomes

  1. The Change of Insomnia Severity from Baseline to Follow-up

    The insomnia severity is assessed with the Insomnia Severity Index (ISI), a 7-item questionnaire well validated in insomnia research in multiple patient populations. The change of ISI scores from baseline to follow-up is the primary outcome.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

Secondary outcomes

  1. Insomnia Remission

    Insomnia remission was evaluated by a masked assessor using a semi-structured interview.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

  2. Insomnia Treatment Response

    Insomnia treatment response was defined by a decrease in ISI by at least 8 points.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

  3. Sleep Parameters Assessed by Sleep Diary

    Sleep diaries related parameters include time taken to fall asleep (sleep onset latency), wake after sleep onset, total sleep, total time in bed, and sleep efficiency.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

  4. Sleep Quality

    Pittsburgh Sleep Quality Index (PSQI) is used to assess overall sleep quality.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

  5. Depression

    Patient Health Questionnaire-9 (PHQ-9) is used to evaluate the severity of depression.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

  6. Anxiety

    Generalized Anxiety Disorder Scale-7 (GAD-7) is used to evaluate the severity of anxiety.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

  7. Life Quality

    WHOQOL-BREF is used to evaluate the life quality.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

Other outcomes

  1. Adverse Events

    Adverse events will be recorded throughout this trial for evaluating the safety of software.

    Time frame: Baseline, post-intervention, follow-up (3 months after post-intervention)

07

Study locations

5 sites
  • Peking University Sixth Hospital
    Beijing, Beijing 100191, China
  • Peking University First Hospital
    Beijing, Beijing, China
  • Shenzhen Kangning Hospital
    Shenzhen, Guangdong, China
  • The Second Affiliated Hospital of AFMU
    Xi'an, Shaanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05747963
Lead sponsor
Peking University Sixth Hospital
Collaborators
Shenzhen Zeen Health Technology Co., Ltd., Peking University First Hospital, Sichuan Provincial People's Hospital, The Second Affiliated Hospital of AFMU, Shenzhen Kangning Hospital
Responsible party
Hongqiang Sun (Professor, Peking University Sixth Hospital) — Principal investigator
First posted
Feb 28, 2023
Start date
Mar 21, 2023
Primary completion
Mar 21, 2024
Completion
Mar 21, 2024
Last update
Aug 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion